{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:03:54Z","timestamp":1785301434157,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the clinical characteristics and identify prognostic factors in patients with newly diagnosed multiple myeloma (NDMM) who presenting with hypercalcemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed clinical and laboratory data from 82 NDMM patients with hypercalcemia who were admitted to the Department of Hematology at Zhongda Hospital (Southeast University) and Jiangning Hospital (Nanjing Medical University) between January 2015 and December 2024. 80 patients without hypercalcemia were randomly selected as a control group for comparison. Prognostic evaluations were based on overall survival (OS), progression-free survival (PFS), and minimal residual disease (MRD) status. Survival rates were estimated using the Kaplan\u2013Meier method, with univariate analyses performed via the Log-rank test and multivariate analyses utilizing the Cox proportional hazards regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort comprised 82 patients (51 males, 31 females). By the end of the follow-up period, with the median follow-up time was 51 months (range, 6\u2013128): 59 patients had died and 23 were alive. Univariate analysis revealed that cytogenetic abnormalities (detected by FISH), serum creatinine, ferritin, MRD status, and serum calcium levels significantly affected both OS and PFS. Multivariate Cox regression demonstrated that the presence of \u2264 1 FISH abnormality and MRD negativity were independent protective factors for OS. Notably, elevated serum ferritin (\u2265500 ng\/mL), a marker previously underexplored in this context, emerged as a robust independent risk factor for both OS and PFS. Severe hypercalcemia (\u22653.5 mmol\/L) was also identified as an independent risk factor for both OS and PFS. For PFS, MRD negativity remained an independent protective factor, whereas ferritin \u2265500 ng\/mL and serum calcium \u22653.5 mmol\/L were identified as independent risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NDMM patients with hypercalcemia exhibited a substantial tumor burden, heterogeneous clinical manifestations, and a high rate of early mortality. Prompt correction of serum calcium levels, with adjustment for concurrent hypoalbuminemia, is imperative. Early detection and optimal management of hypercalcemia are essential to refining treatment strategies and improving survival outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1900926","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:47:52Z","timestamp":1785300472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with hypercalcemia: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lin","family":"Gui","sequence":"first","affiliation":[{"name":"Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhongda Hospital Southeast University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1182\/blood.2024025624","article-title":"Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the IStopMM Screening Study","volume":"145","author":"J\u00f3nsd\u00f3ttir","year":"2025","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/ar2168","article-title":"Multiple myeloma\/hypercalcemia","volume":"9","author":"Oyajobi","year":"2007","journal-title":"Arthritis Res Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.06.025","article-title":"Analysis of non-genetic factors influencing the overall survival of multiple myeloma patients","volume":"28","author":"Gui","year":"2020","journal-title":"Zhongguo shi yan xue ye xue za zhi."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the bone working group of the international myeloma working group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ajem.2021.11.013","article-title":"Severe hypercalcemia requiring acute hemodialysis: a retrospective cohort study with increased incidence during the Covid-19 pandemic","volume":"51","author":"Bentata","year":"2022","journal-title":"Am J Emerg Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bcr-2016-218694","article-title":"Acute confusional syndrome as first manifestation of primary hyperparathyroidism","volume":"31","author":"Pino Rivero","year":"2004","journal-title":"An Otorrinolaringol Ibero Am."},{"key":"B7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1871529X23666221205143041","article-title":"Two-way road of kidney and hypercalcemia: a narrative review","volume":"22","author":"Aghsaeifard","year":"2023","journal-title":"Cardiovasc Hematol Disord Drug Targets."},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.amjmed.2014.09.030","article-title":"Hypercalcemic crisis: a clinical review","volume":"128","author":"Ahmad","year":"2015","journal-title":"Am J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/1097-0142(19820601)49:11","article-title":"Hypercalcemia associated with gynecologic malignancies: biochemical characterization","volume":"49","author":"Stewart","year":"1982","journal-title":"Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.bbagen.2010.03.011","article-title":"Serum ferritin: past present and future","volume":"1800","author":"Wang","year":"2010","journal-title":"Biochim Biophys Acta."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.7314\/APJCP.2014.15.15.6099","article-title":"Elevated serum ferritin levels in patients with hematologic malignancies","volume":"15","author":"Zhang","year":"2014","journal-title":"Asian Pac J Cancer Prev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/1354750X.2025.2485142","article-title":"Serum ferritin can serve as a biomarker for the prognosis and increased the prognostic predictive value of ISS\/RISS in multiple myeloma patients","volume":"30","author":"Dong","year":"2025","journal-title":"Biomarkers Biochem Indic Expo Resp Suscept Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/00003072-198812000-00004","article-title":"Non-osseous bone scan abnormalities in multiple myeloma associated with hypercalcemia","volume":"13","author":"Eagel","year":"1988","journal-title":"Clin Nucl Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1590\/S0004-27302005000500024","article-title":"Hypercalcemia of malignancy: clinical features, diagnosis and treatment","volume":"49","author":"de","year":"2005","journal-title":"Arq Bras Endocrinol Metabol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1039490","DOI":"10.3389\/fendo.2023.1039490","article-title":"Cancer-related hypercalcemia and potential treatments","volume":"14","author":"Almuradova","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"109074","DOI":"10.1016\/j.ymgme.2025.109074","article-title":"Challenges in gaucher disease: perspectives from an expert panel","volume":"145","author":"Grabowski","year":"2025","journal-title":"Mol Genet Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"110489","DOI":"10.1016\/j.resuscitation.2025.110489","article-title":"Pharmacological interventions for the acute treatment of hyperkalaemia: a systematic review and meta-analysis","volume":"208","author":"Jessen","year":"2025","journal-title":"Resuscitation."},{"key":"B21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/08860220902779822","article-title":"Renal disease is a prodrome of multiple myeloma: an analysis of 50 patients from Eastern India","volume":"31","author":"Prakash","year":"2009","journal-title":"Ren Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3760\/cma.j.issn.0253-2727.2023.02.010","article-title":"The influencing factors of renal response in newly diagnosed multiple myeloma patients with renal impairment","volume":"44","author":"Song","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e88087","DOI":"10.7759\/cureus.88087","article-title":"Outcomes of calcium-channel blocker use in patients with multiple myeloma: a propensity-matched study from the global federated health research network","volume":"17","author":"Eidbo","year":"2025","journal-title":"Cureus."},{"key":"B24","doi-asserted-by":"publisher","first-page":"8962","DOI":"10.1002\/cam4.3594","article-title":"Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients","volume":"9","author":"Bao","year":"2020","journal-title":"Cancer Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ejh.12923","article-title":"Greek Myeloma Study Group. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies","volume":"99","author":"Zagouri","year":"2017","journal-title":"Eur J Haematol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1900926\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:48:01Z","timestamp":1785300481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1900926\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":25,"alternative-id":["10.3389\/fmed.2026.1900926"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1900926","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1900926"}}